Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
- Improved accuracy rate to 85% from 80% in excretion odor detection
- Partnership with leading Japanese robotics company for AI Nose integration
- Large market opportunity with electronic nose market projected to reach $76.5B by 2032
- Clear commercial rollout timeline starting H2 2025
- 13 years of accumulated scent data across healthcare use-cases
- Commercial revenue still pending with rollout starting in H2 2025
- Limited initial geographical focus on Japan and Taiwan markets
- 85% accuracy rate still leaves room for potential false positives/negatives
Insights
Ainos' AI Nose accuracy improvement to 85% demonstrates meaningful progress toward commercial viability in the crucial elder care hygiene monitoring market.
Ainos has achieved a meaningful technical milestone with its AI Nose platform improving detection accuracy to
The technology leverages MEMS gas sensors combined with AI models trained on 13 years of scent data. What makes this development particularly notable is the non-contact nature of the monitoring system, which preserves dignity for elderly patients while addressing critical gaps in care. The platform's design flexibility for integration into portable devices, ambient monitors, or robots enhances its market potential.
From a market perspective, Ainos is targeting two of the most rapidly aging societies globally. Japan's caregiver shortage of 570,000+ professionals creates an urgent need for technology-assisted solutions. The timing aligns with Japan's Society 5.0 and Healthcare DX initiatives and Taiwan's Long-Term Care 2.0 program—government-backed frameworks that could accelerate adoption.
The commercial timeline suggests pilot deployments in H2 2025 with full commercialization in 2026, initially in Japan before expanding regionally. The partnership with a leading Japanese robotics company represents a potentially significant distribution channel. With the electronic nose market projected to reach
Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care
SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately
SmellTech for Digitized, AI-Powered Long-term Care
AI Nose digitizes scent into Smell IDs using MEMS gas sensors and proprietary AI models harnessing 13 years of scent data across healthcare and industrial use-cases. Its compact, embedded-ready design enables seamless integration into portable devices, ambient monitors, or robotic platforms.
Ainos is aiming to address the aging population by aligning with government efforts to digitize aging care and reduce institutional burden.
Ainos targets high-impact use cases in long-term care for seniors, including:
Automated hygiene alerts for excretion odor events
Early detection of incontinence in home and facility settings
Scent-triggered workflow optimization to reduce caregiver fatigue
Scent-driven early intervention to reduce skin injuries and infections
Japan and Taiwan Face Alarming Demographic Pressure
Japan: Nearly
30% of population are aged 65+ as of 2024, projected to reach approximately35% by 2040 with a shortage of over 570,000 caregiversTaiwan: Over
20% of the population will be 65+ by 2025, making it a "super-aged" society
Japan and Taiwan are doubling down on robotic and AI-assisted care through initiatives like Society 5.0, Healthcare DX, and Taiwan's Long-Term Care 2.0. Ainos' AI Nose aims to support these national priorities by delivering precision, automation, and labor cost relief.
Commercial Rollout Timeline
Second half of 2025: Continued pilot deployment and field validation in Japan
2026: Commercial rollout targeting LTC institutions in Japan and expansion into other Asia-Pacific regions
Ainos is also partnering with Japan's leading service robotics company to embed AI Nose into autonomous robots, bringing olfaction into smart care infrastructure for the first time.
SmellTech: A
Ainos is pioneering SmellTech as a new category of machine perception. The global electronic nose market is forecast to grow from
With solid validation, real-world deployment in progress, and deep IP, Ainos is positioned to capture first-mover advantage in this rapidly scaling sector.
Human-Centric Vision and Corporate Responsibility
"I believe AI Nose is a new sensory layer for healthcare," said Chun-Hsien (Eddy) Tsai, Chairman, President and CEO of Ainos. "We design this platform to meet real human needs: protecting dignity, reducing labor pressure, and enabling smarter aging care. With Japan and Taiwan both facing demographic cliffs, this milestone proves that smell-driven automation can be a game-changer."
While Ainos pursues innovation and commercialization, the development of its bio-inspired electronic nose technology is fundamentally guided by a humanitarian mission. The company is dedicated to enhancing the quality of life for the elderly, alleviating long-term societal care burdens, and promoting dignity and harmony within caregiving environments and families.
"We may be a technology company, but our purpose is deeply human," said Tsai. "AI Nose represents more than a breakthrough in digital scent-it's Ainos' promise to confront the aging crisis with compassion and to protect the dignity of those we love."
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the new accuracy rate of Ainos (AIMD) AI Nose technology?
When will Ainos (AIMD) begin commercial rollout of AI Nose?
What is the market size for electronic nose technology?
What are the main applications of Ainos (AIMD) AI Nose in elderly care?
Who is Ainos (AIMD) partnering with for AI Nose integration?
